CClinicalTrials.gg
Not yet recruitingNCT07706387Updated Jul 15, 2026

Virgin Coconut Oil Versus Chlorhexidine Mouthwash in Non-Surgical Periodontal Therapy of Periodontitis Patients. A Randomized Controlled Clinical Trial With Biochemical Assessment.

An interventional study of Non-surgical periodontal therapy and Chlorhexidine mouthwash in Stage II Periodontitis, sponsored by Ain Shams University. Not yet recruiting at 1 site in Egypt. Open to participants aged 30 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
30 Years to 50 Years
Sex
All
01

Study summary

This randomized controlled clinical trial will evaluate the effect of virgin coconut oil mouthwash compared with chlorhexidine mouthwash as an adjunct to non-surgical periodontal therapy in patients with stage II periodontitis. Participants will receive scaling and root planing, followed by the assigned mouthwash for 30 days. Clinical periodontal parameters, including plaque index, gingival index, bleeding on probing, probing pocket depth, and clinical attachment level, will be recorded. Gingival crevicular fluid samples will also be collected to assess tumor necrosis factor-alpha levels before and after mouthwash use. The study aims to compare the clinical and biochemical effects of the two mouthwashes.

02

Conditions studied

  • Stage II Periodontitis

Browse trials for

Keywords

  • Stage II periodontitis
  • virgin coconut oil mouthwash
  • TNF-alpha
  • Chlorhexidine mouthwash
  • Non-surgical periodontal therapy
03

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 1. Both genders. 2. Age (30-50) years old. 3. Systemically free according to the modified Burkett's health history questionnaire .

    4. Generalized Periodontitis Stage II . 5. Having at least 20 tooth excluding wisdoms. 6. No history of dental visit in past three months. 7. Participants willing to commit for the entire period of the trial and agreed to sign the written consent after full explanation of the study.

Exclusion criteria

Exclusion Criteria:

  • 1. Smokers. 2. Status of Pregnancy or Contraceptives usage. 3. Allergy to coconut oil . 4. Previous Periodontal treatment within the last 6 months. 5. Antibiotic and/or Anti-inflammatory therapy within the last 6 months.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Active comparator
    Chlorhexidine mouthwash group.

    Patients with Stage II periodontitis will receive non-surgical periodontal therapy followed by chlorhexidine mouthwash according to the study protocol.

    Procedure: Non-surgical periodontal therapy · Other: Chlorhexidine mouthwash

  • Experimental
    Virgin coconut oil mouthwash group.

    Patients with Stage II periodontitis will receive non-surgical periodontal therapy followed by virgin coconut oil mouthwash according to the study protocol.

    Procedure: Non-surgical periodontal therapy · Other: Virgin coconut oil mouthwash

Interventions

  • ProcedureNon-surgical periodontal therapy

    Full-mouth supra- and subgingival scaling and root planing will be performed as part of phase I periodontal therapy.

  • OtherChlorhexidine mouthwash

    Chlorhexidine mouthwash will be used as an adjunct to non-surgical periodontal therapy according to the assigned treatment protocol.

  • OtherVirgin coconut oil mouthwash

    Virgin coconut oil mouthwash will be used as an adjunct to non-surgical periodontal therapy according to the assigned treatment protocol.

05

What researchers measure

Primary outcomes

  1. Clinical attachment level(CAL)

    Clinical attachment level (CAL) will be measured in millimeters from the cementoenamel junction to the base of the periodontal pocket using a manual Michigan O periodontal probe with Williams markings. Measurements will be recorded at six sites per tooth for all teeth, excluding third molars. The mean CAL value will be calculated and recorded for each patient.

    Time frame: From baseline (48 hours after non-surgical periodontal therapy) to 4 weeks after mouthwash use.

  2. Periodontal pocket depth(PPD)

    Periodontal pocket depth (PPD) will be measured in millimeters from the gingival margin to the base of the periodontal pocket using a manual Michigan O periodontal probe with Williams markings. Measurements will be recorded at six sites per tooth for all teeth, excluding third molars. The mean PPD value will be calculated and recorded for each patient.

    Time frame: From baseline (48 hours after non-surgical periodontal therapy) to 4 weeks after mouthwash use

  3. Plaque Index(PI)

    Plaque index (PI) will be assessed on the buccal and lingual surfaces of all teeth using a standardized 0-3 clinical scoring system. The mean PI score will be calculated and recorded for each patient. Surfaces with PI scores of 1, 2, or 3 will also be considered plaque-positive, and the percentage of plaque-positive surfaces will be calculated.

    Time frame: From baseline (48 hours after non-surgical periodontal therapy) to 4 weeks after mouthwash use

  4. Gingival index(GI)

    Gingival index (GI) will be assessed on the buccal and lingual surfaces of all teeth using a standardized 0-3 clinical scoring system. The mean GI score will be calculated and recorded for each patient. Surfaces with GI scores of 1, 2, or 3 will also be considered inflammation-positive, and the percentage of inflammation-positive surfaces will be calculated.

    Time frame: From baseline (48 hours after non-surgical periodontal therapy) to 4 weeks after mouthwash use

  5. Sulcus bleeding index (SBI)

    Sulcus bleeding index (SBI) will be assessed after gentle probing of the gingival sulcus using a standardized 0-3 clinical scoring system. The mean SBI score will be calculated and recorded for each patient. Sites with SBI scores of 1, 2, or 3 will also be considered bleeding-positive, and the percentage of bleeding-positive sites will be calculated.

    Time frame: From baseline (48 hours after non-surgical periodontal therapy) to 4 weeks after mouthwash use

Secondary outcomes

  1. Change in gingival crevicular fluid TNF-alpha level

    Tumor necrosis factor-alpha (TNF-alpha) level will be measured in gingival crevicular fluid (GCF) samples collected using sterile perio paper strips. Samples will be analyzed using enzyme-linked immunosorbent assay (ELISA), and TNF-alpha concentration will be recorded for each patient.

    Time frame: From baseline (48 hours after non-surgical periodontal therapy) to 4 weeks after mouthwash use

  2. Patient satisfaction regarding mouthwash-related side effects

    Patient satisfaction regarding mouthwash-related side effects will be assessed using a patient questionnaire and clinical inspection after mouthwash use. The assessment will include taste alteration, tooth staining, supragingival calculus accumulation, and overall satisfaction with mouthwash use. Responses and clinical findings will be recorded and summarized for each patient

    Time frame: At 4 weeks after mouthwash use.

06

Study locations

1 site
  • Faculty of Dentistry,Ain Shams University
    Cairo, Cairo Governorate 11566, Egypt
07

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. Only aggregated and de-identified results will be reported in the thesis and any related publications. Individual-level data will be kept confidential and accessible only to the study investigators, according to the informed consent and institutional ethics approval.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07706387
Lead sponsor
Ain Shams University
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Jul 2026 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jul 15, 2026

Study contacts

WASIM JOUMA ALHAYEK, B.D.S.
Contact
doctor.wasem.94@gmail.com
+201023828515
Yasmine El-Sayed Fouad, Ass.Lecture
Contact
+201005793929
Ahmed Amr, Professor
study director · Faculty of dentistry-Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion